Efficacy and safety profile of dMMR/MSI immunotherapy in metastatic colorectal cancer in real-world clinical practice
Open Access
- 7 September 2026
- journal article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 18-25
Abstract
Introduction. Deficiency of the mismatch repair system (dMMR) and microsatellite instability (MSI) occur in only 4–5% of patients with metastatic colorectal cancer (mCRC), but this molecular subgroup is characterized by high sensitivity to immune checkpoint inhibitors. Data on the efficacy and safety of such therapy in the Russian population are limited, making this study relevant for real-world clinical practice. Aim. Evaluation of the efficacy and safety of immunotherapy in patients with mCRC and MSI. Materials and methods. This retrospective, multicenter, multicohort, non-randomized study included 74 patients (36 men and 38 women) aged 19 to 85 years. The median follow-up was 41.2 months. Patients received monotherapy (pembrolizumab, nivolumab) or a combination (nivolumab and ipilimumab). An objective tumor response to treatment was defined as partial or complete tumor regression. Tumor response to treatment was determined using iRECIST criteria. Results. Progression-free survival in patients with MSI-positive mCRC was 45.53 months (95% CI: 12.26 – ∞ months) in the monoimmunotherapy group and was not achieved in the combination therapy group, p < 0.05. Overall survival was 45.76 months (95% CI: 25.78 – ∞ months) in the monoimmunotherapy group and was not achieved in the combination therapy group, p < 0.05. Objective response was achieved in 18 (46%) patients in the monoimmunotherapy group and in 19 (54.30%) patients in the combination therapy group. Immune-mediated adverse events of grade 3–4 were observed only in 11 (11.86%) patients. Conclusion. The use of immunotherapy in mCRC with MSI allows achieving high rates of objective response and disease control (50% and 75.7%, respectively) with a favorable safety profile (severe complications – 11.86%).Keywords
This publication has 12 references indexed in Scilit:
- Cancer statistics, 2026CA: A Cancer Journal for Clinicians, 2026
- The efficacy of Pembrolizumab, Ipilimumab, and Nivolumab monotherapy and combination for colorectal cancer: A systematic review and meta-analysisPLOS ONE, 2025
- Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trialThe Lancet, 2025
- Рак ободочной кишки, ректосигмоидного соединения и прямой кишкиMalignant tumours, 2024
- Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA: A Cancer Journal for Clinicians, 2024
- Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patientsEuropean Journal of Cancer, 2024
- Molecular genetic characteristics of colorectal cancer depending on the status of microsatellite instabilityMeditsinskiy sovet = Medical Council, 2022
- Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.Journal of Clinical Oncology, 2022
- Combined immunotherapy of colorectal cancer in young patient with microsatellite instability (clinical case)Medical alphabet, 2021
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal CancerJournal of Clinical Oncology, 2018